Lead Product(s) : Bofanglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gan & Lee Start US Phase 2 Bofanglutide Trial for Overweight & Obesity Patients
Details : GZR18 (Bofanglutide) tablet is an investigational, once-daily oral GLP-1 receptor agonist, which is being developing for the treatment of obesity.
Product Name : GZR18
Product Type : Peptide
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Bofanglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bofanglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gan & Lee Announces U.S. FDA Clearance for Bofanglutide in Chronic Weight Management
Details : GZR18 (bofanglutide) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed for type 2 diabetes and chronic weight management for obese or overweight patients.
Product Name : GZR18
Product Type : Peptide
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : Bofanglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ECC5004
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : $2,010.0 million
Deal Type : Licensing Agreement
Eccogene Earns $60M Milestone from AstraZeneca for Obesity, Diabetes Drug
Details : AstraZeneca has licensed global rights to ECC5004/AZD5004 from Eccogene. ECC5004 is currently undergoing mid-stage clinical trials for the treatment of obesity and Type 2 diabetes.
Product Name : ECC5004
Product Type : Other Small Molecule
Upfront Cash : $185.0 million
October 23, 2024
Lead Product(s) : ECC5004
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : $2,010.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI362 (Mazdutide) is a GLP-1R and GCGR dual agonist peptide, subcutaneous injection, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
October 29, 2023
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XW003 is a novel, biased long-lasting GLP-1 peptide analogue optimized for improved biological activity and once weekly dosing. GLP-1 analogs are effective tools in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatmen...
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mazdutide (IBI362) is a long-acting synthetic peptide related to mammalian OXM, which uses a fatty acid side chain to prolong the duration of action and allow once-weekly administration.In higher-dose cohorts, mazdutide up-titrated to 10 mg and 9 mg were...
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI362 having mazdutide is a long-acting synthetic peptide related to mammalian oxyntomodulin (OXM), which uses a fatty acid side chain to prolong the duration of action and allow once-weekly administration.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In cohort 1-3 (low-dose), IBI362 (mazdutide) demonstrated favorable tolerability and a safety profile, with mean percent reduction from baseline in body weight of up to 6.4% for participants receiving mazdutide at week 12.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
June 13, 2022
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At Week 24, each dose of IBI362 (mazdutide) showed significant efficacy on body weight loss compared with placebo in a dose-dependent manner and brought multiple cardio-metabolic benefits to participants.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable